Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC13A5 | Q86YT5 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766065 | 0.91 | SLC13A5 (0.64) | SLC13A5KMT2AMEN1NPC1RAB9A | |
| SCHEMBL21765927 | 0.85 | GAA (0.67) | SLC13A5KMT2AMEN1NPC1PKM | |
| SCHEMBL21766091 | 0.84 | SLC13A5 (0.59) | SLC13A5KMT2AMEN1NPC1PKM | |
| SCHEMBL21766081 | 0.82 | SLC13A5 (0.61) | SLC13A5KMT2AMEN1NPC1PKM | |
| SCHEMBL20258790 | 0.81 | ACKR3 (0.48) | KMT2AMEN1NPC1ALDH1A1ACKR3 | |
| SCHEMBL21765929 | 0.81 | SLC13A5 (0.79) | SLC13A5KMT2APKMALDH1A1LMNA | |
| SCHEMBL21766044 | 0.79 | SLC13A5 (0.65) | SLC13A5KMT2AMEN1NPC1PKM | |
| SCHEMBL21766054 | 0.78 | SLC13A5 (0.62) | SLC13A5KMT2APKMALDH1A1GAA | |
| SCHEMBL21766085 | 0.77 | SLC13A5 (0.63) | SLC13A5KMT2AMEN1PKMALDH1A1 | |
| SCHEMBL21766036 | 0.77 | SLC13A5 (0.54) | SLC13A5KMT2AMEN1PKMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10793522-B2 | Sulfonamides as inhibitors of the uptake of extracellular citrate | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-10-06 | — | — | US | disclosed |
| EP-3551618-B1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | BOEHRINGER INGELHEIM INT (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-20200062708-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | BOEHRINGER INGELHEIM PHARMA GBMH & CO KG (DE) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062708-A1 | SULFONAMIDES AS INHIBITORS OF THE UPTAKE OF EXTRACELLULAR CITRATE | CS, GLS, GLS2 | SLC13A5 261/4885KMT2A 3613/4885MEN1 2286/4885 |
| US-10793522-B2 | Sulfonamides as inhibitors of the uptake of extracellular citrate | CS, GLS, GLS2 | SLC13A5 261/4885KMT2A 3613/4885MEN1 2286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.